Suche

Adcetris

Brentuximab vedotin · L01FX05

Padcev

Enfortumab vedotin · L01FX13

Polivy

polatuzumab vedotin · L01FX14

Tivdak

tisotumab vedotin · L01FX23

Bullöse Dermatose (L13.9) Differenzialdiagnostik und Therapie‑Standard

Bullöse Dermatose, nicht näher bezeichnet (BD‑N) ist ein Sammelbegriff für klinisch manifestierte, flüssigkeitsgefüllte Hautbläschen ohne eindeutige histopathologische Zuordnung zu einer spezifischen Dermatitisform. Die Prävalenz ist …

Adcetris · 4.5 · Co-administration of brentuximab vedotin did not affect the plasma exposure of AVD.

Adcetris · 4.5 · Co-administration of brentuximab vedotin is not expected to affect the exposure of CHP.

Adcetris · 4.5 · Co-administration of brentuximab vedotin with ketoconazole, a strong CYP3A4 and P-gp inhibitor, increased the

Adcetris · 4.5 · Co-administration of brentuximab vedotin with rifampicin, a strong CYP3A4 inducer, did not alter the plasma ex

Adcetris · 4.5 · Co-administration of midazolam, a CYP3A4 substrate, with brentuximab vedotin did not alter the metabolism of m

Adcetris · 4.5 · There were no formal drug-drug interaction studies with brentuximab vedotin and bleomycin (B). In a phase 1 do

Safety and preliminary efficacy of Disitamab Vedotin combined with Toripalimab and concurrent radiotherapy in bladder-preserving treatment for HER2-positive invasive bladder cancer

pubmed · 42459305

Enfortumab vedotin-induced bullous dermatitis

pubmed · 40991477

Enfortumab vedotin therapy complicated by bullous dermatitis: A case report

pubmed · 40530174